Literature DB >> 21492165

A synthetic cannabinoid, CP55940, inhibits lipopolysaccharide-induced cytokine mRNA expression in a cannabinoid receptor-independent mechanism in rat cerebellar granule cells.

Toshiki Chiba1, Sanae Ueno, Yutaro Obara, Norimichi Nakahata.   

Abstract

OBJECTIVES: The inflammatory response plays an important role in the pathogenesis of many diseases in the central nervous system. Cannabinoids exhibit diverse pharmacological actions including anti-inflammatory activity. In this study, we tried to elucidate possible effects of cannabinoids on lipopolysaccharide (LPS)-induced expression of inflammatory cytokine mRNAs in rat cerebellar granule cells.
METHODS: Inhibitory effects of cannabinoids on cytokine induction in cerebellar granule cells were determined by RT-PCR method. KEY
FINDINGS: In these cells, both mRNA and protein of cannabinoid receptor 1 (CB(1) ), but not CB(2) , were expressed. LPS (1 µg/ml) produced a marked increase in the induction of inflammatory cytokines, including interleukin-1β, interleukin-6 and tumour necrosis factor-α. CP55940, a synthetic cannabinoid analogue, concentration-dependently inhibited inflammatory cytokine expression induced by LPS. On the other hand, the endocannabinoids 2-arachidonoylglycerol and anandamide were not able to inhibit this inflammatory response. Notably, a CB(1) /CB(2) antagonist NESS0327 (3 µm) did not reverse the inhibition of cytokine mRNA expression induced by CP55940. GPR55, a putative novel cannabinoid receptor, mRNA was also expressed in cerebellar granule cells. Although it has been suggested that G(q) associates with GPR55, cannabinoids including CP55940 did not promote phosphoinositide hydrolysis and consequent elevation of intracellular Ca([2+]) concentration. Furthermore, a putative GPR55 antagonist, cannabidiol, also showed a similar inhibitory effect to that of CP55940.
CONCLUSIONS: These results suggest that the synthetic cannabinoid CP55940 negatively modulates cytokine mRNA expression in cerebellar granule cells by a CB and GPR55 receptor-independent mechanism.
© 2011 The Authors. JPP © 2011 Royal Pharmaceutical Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21492165     DOI: 10.1111/j.2042-7158.2011.01250.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  5 in total

Review 1.  Endocannabinoids in cerebrovascular regulation.

Authors:  Zoltán Benyó; Éva Ruisanchez; Miriam Leszl-Ishiguro; Péter Sándor; Pál Pacher
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-01-29       Impact factor: 4.733

Review 2.  Minireview: recent developments in the physiology and pathology of the lysophosphatidylinositol-sensitive receptor GPR55.

Authors:  Christopher M Henstridge; Nariman A B Balenga; Julia Kargl; Clara Andradas; Andrew J Brown; Andrew Irving; Cristina Sanchez; Maria Waldhoer
Journal:  Mol Endocrinol       Date:  2011-09-29

Review 3.  Effects of Cannabidiol on Locomotor Activity.

Authors:  Fabrizio Calapai; Luigi Cardia; Gioacchino Calapai; Debora Di Mauro; Fabio Trimarchi; Ilaria Ammendolia; Carmen Mannucci
Journal:  Life (Basel)       Date:  2022-04-27

Review 4.  Cannabinoid and endocannabinoid system: a promising therapeutic intervention for multiple sclerosis.

Authors:  Hina Khan; Fareeha Khalid Ghori; Uzma Ghani; Aneela Javed; Saadia Zahid
Journal:  Mol Biol Rep       Date:  2022-02-18       Impact factor: 2.742

5.  Lysophosphatidylinositol causes neurite retraction via GPR55, G13 and RhoA in PC12 cells.

Authors:  Yutaro Obara; Sanae Ueno; Yoshimi Yanagihata; Norimichi Nakahata
Journal:  PLoS One       Date:  2011-08-31       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.